An Exploratory Study of Near-infrared Light Therapy for Mild to Moderate Alzheimer's Disease

Prior treatment

• Currently taking anticoagulant drugs;
• Severe head trauma or implants (bone nails, bone plates, excision, etc.);
• Persons addicted to alcohol or drugs;
• Participated in other clinical studies within 1 month before participating in this trial;

Other illness

• Any cognitive impairment or dementia not caused by Alzheimer's disease, or co-existing with a serious mental illness (schizophrenia, bipolar disorder, major depression, etc.);
• A history of seizures or hemorrhagic stroke within 12 months;
• Allergic to sunlight or visible light or high sensitivity to head and neck skin;
• Malignant tumors;
• Any other medical condition that is not stabilized and adequately controlled (such as serious heart, respiratory, gastrointestinal, or kidney disease), or that the investigator believes may affect patient safety or interfere with the evaluation of the test;
• Other conditions deemed unsuitable for clinical trial participation by the investigator.

Other

• Women who are pregnant, nursing or planning a pregnancy;

• 50 - 90 years old, no gender limitation;
• Meeting the National Institute on Aging and Alzheimer's Association (2011 NIA-AA) is likely the core clinical diagnostic criteria for Alzheimer's disease;
• The MMSE score is ≥ 12 and ≤ 26;
• The subjects should have primary school education or above and be able to complete the cognitive ability measurement and other tests stipulated in the protocol;
• If taking cognitive-improving medications, the dose must be stable for at least 12 weeks prior to enrollment (stable for at least 4 weeks with psychotropic medications);
• Participants themselves or their guardians voluntarily participate and sign the informed consent.